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ABSTRACT
The purpose of this research was to evaluate the inclusion complex composed of osthole and hydroxypropyl-β-cyclodextrin
(HP-β-CD) by using two preparative techniques, neutralization and high-pressure homogenization (HPH) method. The solid
complexes were characterized by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), particle
size determination, and dissolution test. The DSC diagrams indicated that the solid complex from the HPH method led to more
complete complexation than that of physical mixture and neutralization method. The formation of inclusion complex between drug
and cyclodextrin (CD) was verified by FTIR analysis. The smallest mean particle size of solid complex was acquired from the HPH
method. The results proved that the rate of drug release for the inclusion complex obtained from the HPH method was much faster
than those of neutralization, physical mixture, HP-β-CD and osthole alone.
Key words: osthole, hydroxypropyl-β-cyclodextrin, high-pressure homogenization method, neutralization, solubility

INTRODUCTION
The dried fruits of Cnidium monnieri (L.) Cusson,
Cnidium monnieri Fructus, belonging to the Umbelliferae family were called “She chuang zi” in China and
have been used in oriental countries for centuries as a
philter or tonic(1). Osthole [C15H16O3, 7-Methoxy-8-(3methyl-2-butenyl)-2H-1-benzopyran-2-one], a coumarin
derivative, is an effective ingredient extracted from the
fruit of Cnidium monnieri and possesses several curative properties(2). Previous studies on osthole revealed
various pharmacological activities, such as anti-allergic
effects(3), anti-inflammatory effects(4), anti-proliferative
effects(5), vasorelaxation(6), anti-tumor effects(7), improvement of aspects of spatial performance(8), nonspecific
relaxant effects on the trachealis(9), respiratory stimulant
effects(10,11), relaxation of corpus cavernosum tissue(12)
and treatment of osteoporosis(13).
As far as physicochemical properties are concerned,
applications of osthole are still confined on account of
its poor water solubility. Chemical and physical modifications have been employed to enhance the solubility
of poor water-soluble drugs or enlarge available surface
* Author for correspondence. Tel: +886-7-3121101 ext. 2254;
Fax: +886-7-3210683; E-mail: chamtm@kmu.edu.tw

areas of dissolution(14). In recent decades, applications
of CDs in the pharmaceutical field, analytical chemistry,
agriculture and cosmetics were developed. Numerous
advantages of CD complex for drug delivery systems
were also verified, such as enhancement of solubility,
improvement of bioavailability of hydrophobic drugs,
domination of crystallization and polymorphic transition of drugs, controlled release of hydrophilic drugs,
stabilization of peptide, oxygen-, and light-sensitive
drugs, disguise of indisposed taste and smell, fixation of
extremely volatile drugs and prevention of degradation of
drugs (15,16). The chemical structures of CD derivatives,
cyclic oligosaccharides consist of (α-1, 4)-linked glucopyranose subunits, similar to a skirt-shape construction,
produce a hydrophobic internal cavity and hydrophilic
outer surface. CDs are able to interact with suitable drugs
to generate the formation of inclusion complexes by
various preparation methods(16-18).
The objective of this research is to study physicochemical characterizations of CD inclusion complexes
prepared by physical mixture, neutralization and HPH
method. Phase-solubility measurement, FTIR analysis,
DSC study, particle size analysis and dissolution test were
utilized for evaluation. The HPH method of preparing
osthole-HP-β-CD inclusion complexes has not been
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published before. This method does not use toxic chemicals, so there is no concern of noxious chemicals residues.
The aim of CD inclusion complexes was to increase the
solubility and dissolution rate of osthole. The results indicated that the HPH method may be applied to improve the
solubility and dissolution of osthole.

MATERIALS AND METHODS

IV. Preparation of Solid Inclusion Complex

I. Chemicals
Osthole was kindly supplied by Dr. Chien-Chih Yu
from Sheng Chun Tang Pharmaceutical Industrial Co.,
Ltd. (Tainan, Taiwan, R.O.C.). The purity of osthole was
above 99%. HP-β-CD was purchased from Roquette Ltd.
(Lestrem, France). Honokiol was obtained from Sigma
Chemical Co. (St. Louis, MO, USA). All other materials
were of analytical or high performance liquid chromatography (HPLC) grade.
II. Phase-Solubility Measurement
Phase-solubility measurement was performed based
on the formula from Higuchi and Connors (19) to investigate the preferable complex ratio of osthole and HP-βCD. A surplus of osthole was added to 10 mL of deionized water, which consisted of diverse concentrations
of HP-β-CD (1 - 100 mM). The resulting mixtures were
sufficiently equilibrated in a thermostatic shaking
water bath for 72 h at 25°C. The supernatant was passed
through a 0.45-μm membrane filter to eliminate undissolved solid after equilibration and then analyzed by high
performance liquid chromatography (HPLC) system.
Six determinations were accomplished for each sample.
The result obtained was of 1 : 1 stoichiometry and the
apparent stability constant (Ks) was estimated from the
straight line portion of the phase-solubility diagram in
accordance with the equation:
Ks = slope / [intercept (1 - slope)]

evaluated on fresh osthole standard solutions at 7:00 am,
9:00 am, 11:00 am, 1:00 pm, 3:00 pm and 5:00 pm for 6
successive days, while the intra-day precision was calculated using 6 replicate measurements of osthole within
the same day. The mean, standard deviation (S.D.) and
coefficient of variation (C.V. %) of precision as well as
the relative differences of accuracy were determined to
estimate the stability of HPLC assays.

(1)

where intercept refers to the saturation concentration of the drug appraised without cyclodextrin.
III. HPLC Analysis of Osthole
The analysis of osthole used a LiChrospher ® C18
reversed phase column (5 μm, 250 mm × 4.6 mm i.d.,
Merck, Darmstadt, Germany) at room temperature. A
Hitachi LaChrom Elite HPLC system equipped with a
Hitachi L-2420 UV-Vis Detector (Hitachi, Japan) at 322
nm was used. The mobile phase, adjusted to pH 3.0 with
orthophosphoric acid, consisted of 82% methanol and
18% deionized water at a flow rate of 1 mL/min. The
injection volume was 20 μL and honokiol was employed
as the internal standard. The inter-day precision was

The ideal molar ratio of osthole : HP-β-CD (1 : 1) for
the formation of inclusion complexes were on the strength
of consequences of phase-solubility measurement.
(I) Neutralization Method
Osthole and HP-β-CD were weighed accurately and
added to 100 mL of 1 N sodium hydroxide solution. The
mixture was stirred with a magnetic stirrer in a hood
at 37 ± 2°C until a transparent solution was obtained.
Exactly 100 mL of 1 N hydrochloric acid was added into
the solution and agitated for 3 h. The precipitate was
separated from the solution and washed three times with
absolute ethanol. The precipitate was then evaporated to
dryness at ambient temperature.
(II) Physical Mixture
Osthole and HP-β-CD were precisely weighed
respectively, passed through a 425-μm sieve and then
thoroughly mixed in a mortar.
(III) HPH Method
HP-β-CD was dissolved in deionized water. Then,
osthole dissolved in absolute ethanol was added to the
solution in the molar ratio mentioned above. The whole
solution was immediately passed through a model EmulsiFlex-C3 high-pressure homogenizer (Avestin, Canada)
3 times under an operating pressure of 10,000 psi at room
temperature. The eventual solution was filtered and evaporated to dryness until the solid complex was acquired.
V. FTIR Analysis
Samples were ground and blended with potassium
bromide. A Perkin- Elmer Spectrum System 2000 FTIR
spectrometer (Norwalk, USA) was used for the analysis
in the range between 4000 cm−1 and 400 cm−1 at a resolution of 4 cm−1. The FTIR spectra were obtained from
dried samples and the data were averages of 10 scans.
VI. DSC Study
a

DSC thermogram studies were achieved using
Perkin Elmer model DSC-7 (Norwalk, USA).
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Temperature calibrations were performed with indium
and zinc before analyzing specimens. Four mg of osthole,
HP-β-CD, physical mixture and 2 inclusion complexes
were respectively weighed accurately and heated under
a nitrogen gas flow at a scanning rate of 20°C/min over
a temperature range of 40 - 200°C. Aluminum lids and
pans were utilized for whole samples.
VII. Particle Size Analysis

increased rapidly when HP-β-CD concentration was
further raised in later part of Figure 1(b). On the assumption that the complex formed was of a 1 : 1 stoichiometric
ratio, the apparent stability constant (Ks) of the complex
calculated from the slope of the initial linear portion in
Figure 1(a) of the phase solubility diagram was 6191.1
M-1. Briefly, the 1 : 1 molar ratio of osthole and HP-β-CD
was the preferred composition for forming the inclusion
complex.
II. Validation of HPLC Method

The mean sizes of osthole, HP-β-CD, physical
mixture and 2 inclusion complexes were measured by
LS 230 laser diffraction particle size analyzer from
Beckman Coulter (Miami, USA). Size distributions of
all samples were evaluated by fitting the intensity of the
scattering light (λ = 750 nm) and the scattering angle (θ
= 0.017 - 34°). Ethylene glycol (η = 16.1 mPa·s at 25°C)
was used as the background medium and its index of
refraction was 1.41856. One hundred milligrams of each
sample was adequately dispersed into 200 mL of ethylene
glycol before analysis. Triplicate determinations were
performed for each sample.

The precision and accuracy of intra-day and interday osthole quantification were determined using HPLC.
The calibration curve, ranging between 0.1 and 10 μg/
mL, constructed from osthole exhibited exceptional
linearity with R 2 > 0.999. The coefficient of variance of
precision was from 0.096 to 4.347 and the relative error
of accuracy was from 0.000 to 4.632. Therefore, the
quantification of osthole was adequately acceptable.

VIII. Dissolution Test

(I) DSC Studies

The USP 31 paddle method of dissolution studies
were accomplished with the pharmaceutical dissolution testing model Hanson SR8 Plus (Chatsworth, USA).
Nine hundred mL of deionized water was used as the
dissolution medium. The stirring speed was 100 rpm
and the temperature was maintained at 37 ± 0.5°C. All
powder samples containing an equivalent amount of 10
mg of osthole were respectively placed in the dissolution
medium. One milliliter of each sample was collected at 1,
5, 10, 15, 30, 45, 60 and 120 min. Thereafter, the HPLC
method was applied to determine the sample concentrations. All dissolution tests were executed six times.
Dissolution data were estimated in view of dissolution
efficacy (DE), as an index of totality of processes and the
dissolved percentage of drug (DP), as an indication of
the dissolution rate. DE was defined as the area under the
dissolution curve at time (t) by utilizing the trapezoidal
rule and shown as a percentage of the area of the rectangle
represented by whole dissolution in the same time (20).

DSC curves obtained from osthole, HP-β-CD, physical mixture, complexes from neutralization and HPH
method were shown in Figure 2. Proof of interactions
between osthole and HP-β-CD was acquired by applying
thermal analytical study to verify the formation of solid
complex. The DSC thermogram of pure osthole revealed
a unique representative endothermic melting peak at the
onset temperature of 88.0°C, and the polymorph of osthole
was not detected. The thermal curve of HP-β-CD displayed
a small elevatory curve around 96°C. Furthermore, the
amorphism of HP-β-CD was presented. At 88.0°C, the
thermal behavior of the physical mixture presented a

I. Phase-Solubility Measurement
The phase solubility diagram of osthole with
HP-β-CD determined in water at 25°C was displayed in
Figure 1. The profile of the diagram was similar to an Ap
system(19) and the solubility of osthole measured at 25°C
was 1.81 × 10 -5 M. The solubility of osthole was elevated
slowly following the increase of HP-β-CD concentration
at the initial stage in Figure 1(a). The solubility of osthole
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III. Demonstrations of Osthole Inclusion Complex
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Figure 1. Phase solubility diagram of osthole-HP-β-CD in deionized
water at 25°C (n = 6). (a) represent the initial stage of the diagram of
solubility. (b) represent the last stage of the diagram of solubility.
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conspicuous endothermic melting peak according to thermogram of osthole. The upward diagram of physical
mixture was analogous to the curve of HP-β-CD and the
apex of curve was transferred from 96°C to 111°C in virtue
of interactions between osthole with HP-β-CD.
For the thermogram of solid complex prepared by
neutralization, a slight melting peak at 88.0°C may indicate the existence of small residuals of osthole crystal in
this preparation. No melting peak of inclusion complex
from HPH method was present in whole time intervals,
which is ascribed to the encapsulation of osthole molecules inside HP-β-CD cavities and the formation of
amorphous solid complexes. This signified that sturdy
interactions between osthole and HP-β-CD in the HPH
method and recrystallization was obstructed.

Table 1. Comparison of FTIR spectra of osthole, physical mixture
and inclusion complexes from neutralization and HPH method

Osthole
(cm-1)

Physical
mixture
(cm-1)

Inclusion
complexes
from
neutralization
(cm-1)

Inclusion
complexes
from HPH
method
(cm-1)

Remark

1606

1606

1607

1614

Change in C = C
stretching
vibration

1721

1721

1722

1729

Change in C =
O symmetric
vibration

(1)
(2)

(3)
(4)
(5)
40
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Figure 2. Thermograms of (1) osthole, (2) HP-β-CD, (3) physical
mixture, (4) complex from neutralization method and (5) complex
from HPH method.

(1)
1721 1606

Transmittance (%T)

FTIR spectra of osthole, HP-β-CD, physical mixture,
complex from neutralization and HPH method are
displayed in Figure 3 and Table 1 to substantiate evidence
of solid inclusion complexes between drug and HP-β-CD.
In accordance with Figure 3, it was found that
the FTIR spectrum of carbonyl stretching for pure
osthole signified an angular concave peak at 1721 cm-1.
In comparison with the peak of pure osthole, a shift to
higher frequency and a narrower shape for both inclusion
complexes were shown. The curve of the complex from
neutralization was moved from 1721 to 1722 cm-1. Meanwhile, the peak of the complex from HPH method was
shifted from 1721 to 1729 cm-1. The consequence might
be a result of interaction between the carbonyl group of
osthole and the hydroxylpropyl group of HP-β-CD.
With regard to the band of alkenyl group, the characteristic of pure drug was maintained at 1606 cm-1, while
it shifted to 1607 cm-1 for the complex from neutralization and to 1614 cm-1 for the complex from HPH method.
The curves of C=C stretching vibration for both inclusion
complexes were also narrower with higher frequency.
The causes of these observations might be due to the
interaction between carbon molecules of drug and
hydrogen molecules of HP-β-CD.
The spectrum of physical mixture could be regarded
as the outcome of the blending of osthole and HP-βCD, hence verifying lack of interactions between drug
and CD, as implied by DSC thermogram. However, the
FTIR spectra of inclusion complexes obtained by HPH
method and neutralization revealed some dissimilarities
with reference to those of physical mixture and accordingly exhibited some interactions between drug and
CD. The shift of peaks shown in FTIR spectra relied on
the preparation technique, indicating dissimilar level of
interactions for different products. In brief, no significant
feature of osthole was displayed in the spectra of both
inclusion complexes obtained from neutralization and
HPH method, revealing that the two inclusion complexes
were excellently formed.

Heat Flow (mW)

(II) FTIR Analysis
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Figure 3. FTIR spectra of (1) osthole, (2) HP-β-CD, (3) physical
mixture, (4) complex from neutralization and (5) complex from HPH
method.
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Table 2. Comparison of DE and DP from osthole, physical mixture and inclusion complexes from neutralization and HPH method at 5, 30
and 60 min, respectively
5 min

30 min

60 min

DE

DP

DE

DP

DE

DP

Osthole

0.0011

0.23

0.0050

0.66

0.0065

1.10

Physical mixture

0.0250

5.66

0.1266

20.65

0.1870

29.68

Inclusion complexes from neutralization

0.0604

12.2

0.2992

49.04

0.4308

62.28

Inclusion complexes from HPH method

0.1002

21.3

0.4833

69.02

0.6216

81.09

Table 3. Comparison of particle sizes from osthole, physical mixture and inclusion complexes from neutralization and HPH method

Particle size
Mean ± S.D. (μm)

Osthole

HP-β-CD

Physical mixture

Inclusion complexes
from neutralization

Inclusion complexes
from HPH method

241.9 ± 8.7

154.1 ± 3.3

197.0 ± 3.8

90.6 ± 4.6

60.2 ± 2.6

IV. Particle Size Analysis

V. Dissolution Test
Dissolution curves of complex from HPH method,
complex from neutralization, physical mixture and
osthole were exhibited in Figure 4. Dissolution data
presented as DE and DP at 5, 30 and 60 min were shown
in Table 2. According to the data of Table 2, the DP of
solid complex from HPH method at 5 min was 21.3%,
while the DP of solid complex from neutralization,
physical mixture and osthole was 12.2, 5.66 and 0.23%,
respectively. Even after an hour, the DP of the solid
complex from HPH method (81.09%) was still apparently higher than those of the solid complexes from
neutralization (62.28%), physical mixture (29.68%)

HPH method
Neutralization
Pysical mixture
Osthole

80

Release (%)

The average and standard deviation of particle size
for osthole, HP-β-CD, physical mixture, complex from
neutralization and HPH method are shown in Table 3.
The mean particle size of osthole and HP-β-CD was 241.9
± 8.7 and 154.1 ± 3.3 μm, respectively. Nevertheless, the
mean particle size was 60.2 ± 2.6 μm for the complex
from HPH method and 90.6 ± 4.6 μm for the complex
from neutralization. Owing to bonding collectively from
hydrogen bonding, the particle size of HP-β-CD was
larger than that of two solid complexes. Besides, the
particle size of osthole was also larger than others due
to aggregation during storage. The particle size of the
physical mixture was between that of osthole and HP-βCD. From Table 3, the particle size of the complex from
HPH method was smaller than that of the complex from
neutralization, implying that fractional complexation was
imperfect from the neutralization technique.
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Figure 4. Dissolution curves of complex from HPH method (●),
complex from neutralization (○), physical mixture (▼) and osthole
(r).

and osthole (1.10%). The results demonstrated that
solid complex from HPH method dissolved faster than
the solid complexes from neutralization, physical
mixture and osthole alone. Based on the data from DE,
the DE of the solid complex from HPH method was
much better than others. In terms of the DP and DE at
5, 30 and 60 min, all manifested that the solid complex
from HPH method possessed higher dissolution rate
than others, and the ranking of dissolution rates was
complex from HPH method > complex from neutralization > physical mixture > osthole alone. The increment
of dissolution rate for unsophisticated physical mixture
may be ascribed to the decrement of interfacial tension
between the hydrophobic drug and dissolution medium.
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Furthermore, the improved dissolution performance of
solid complexes could be attributed to the ameliorative
wettability of the drug. Preparation methods utilized for
solid complexes also apparently influenced the performance of dissolution efficacy. The technique of preparative method for the complex from HPH method was superior to that of the complex from neutralization.

CONCLUSIONS
In terms of phase-solubility measurements, 1 : 1
molar ratio of osthole-HP-β-CD inclusion complexes was
designed to prepare for physicochemical characterizations. DSC studies and FTIR analyses were well applied to
substantiate formations of both inclusion complexes. Solid
complexes prepared by neutralization and HPH method
brought about analogous FTIR spectrum, signifying that
both complexes possessed similar characters of solid state.
In addition, it could be reasonably inferred that molecular
interactions of drug and CD might be due to formations
of bonding according to the data from FTIR. From DSC
thermograms, the solid complex obtained by HPH method
completely lacked the melting peak of osthole. On the
contrary, a small peak was present of the inclusion complex
prepared by neutralization method. DSC curves showed
that the technique of HPH preparation method resulted in
more thorough complexation than that of neutralization.
Depending upon particle size analysis, the smallest
particle size of solid complexes was also obtained from
HPH method. Concerning dissolution tests, the dissolution
rate of the inclusion complex from HPH method was more
rapid than those of neutralization and physical mixture. In
summary, the superiority of the HPH technique may be
principally ascribed to the decrement of particle size of
drug and the improvement of drug solubility. The study
indicated that osthole-HP-β-CD complex prepared by
using the HPH method may substantially improve the solubility and dissolution rate of osthole in contrast to those
from physical mixture and neutralization.
Owing to the increase in solubility, the formulation of osthole-CD inclusion complexes may be applied
in various dosage forms, such as ointment for local antiallergic effects, cream for local anti-inflammatory effects,
gel for relaxation of corpus cavernosum tissue and powder
for relaxant effects on the trachealis. In vitro or in vivo
studies, toxicology, pharmacokinetic and related investigations of innovative drug-CD inclusion complexes
obtained from various techniques will be more extensively
studied. The HPH method ought to be experimented with
more drugs and different kinds of CDs to better study the
developmental possibilities of this method.
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